These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 26845886)

  • 1. [CANCER REPROGRAMMING AND ITS CLINICAL APPLICABILITY].
    Konno M; Ishii H; Doki Y; Mori M
    Nihon Geka Gakkai Zasshi; 2015 Nov; 116(6):357-9. PubMed ID: 26845886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs Induce Epigenetic Reprogramming and Suppress Malignant Phenotypes of Human Colon Cancer Cells.
    Ogawa H; Wu X; Kawamoto K; Nishida N; Konno M; Koseki J; Matsui H; Noguchi K; Gotoh N; Yamamoto T; Miyata K; Nishiyama N; Nagano H; Yamamoto H; Obika S; Kataoka K; Doki Y; Mori M; Ishii H
    PLoS One; 2015; 10(5):e0127119. PubMed ID: 25970424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells.
    Ceppi P; Peter ME
    Oncogene; 2014 Jan; 33(3):269-78. PubMed ID: 23455327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis.
    Koturbash I; Zemp FJ; Pogribny I; Kovalchuk O
    Mutat Res; 2011 Jun; 722(2):94-105. PubMed ID: 20472093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the specific epigenetic alterations associated with chemo-resistance via reprogramming of cancer cells.
    Kim JJ; Rai R
    Med Hypotheses; 2015 Dec; 85(6):710-4. PubMed ID: 26527497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reprogramming cancer cells: a novel approach for cancer therapy or a tool for disease-modeling?
    Yilmazer A; de Lázaro I; Taheri H
    Cancer Lett; 2015 Dec; 369(1):1-8. PubMed ID: 26276716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early epigenetic cancer decisions.
    Martín-Lorenzo A; Gonzalez-Herrero I; Rodríguez-Hernández G; García-Ramírez I; Vicente-Dueñas C; Sánchez-García I
    Biol Chem; 2014 Nov; 395(11):1315-20. PubMed ID: 25205718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
    Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
    Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noncoding RNAs in Regulation of Cancer Metabolic Reprogramming.
    Yang D; Sun L; Li Z; Gao P
    Adv Exp Med Biol; 2016; 927():191-215. PubMed ID: 27376736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics.
    Xia H; Hui KM
    Cancer Gene Ther; 2012 Nov; 19(11):723-30. PubMed ID: 22975591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer.
    Garg M
    Expert Opin Ther Targets; 2015 Feb; 19(2):285-97. PubMed ID: 25563894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state.
    Lim YY; Wright JA; Attema JL; Gregory PA; Bert AG; Smith E; Thomas D; Lopez AF; Drew PA; Khew-Goodall Y; Goodall GJ
    J Cell Sci; 2013 May; 126(Pt 10):2256-66. PubMed ID: 23525011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential application of cell reprogramming techniques for cancer research.
    Saito S; Lin YC; Nakamura Y; Eckner R; Wuputra K; Kuo KK; Lin CS; Yokoyama KK
    Cell Mol Life Sci; 2019 Jan; 76(1):45-65. PubMed ID: 30283976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of pancreatic cancer stem cells to reprogramming.
    Noguchi K; Eguchi H; Konno M; Kawamoto K; Nishida N; Koseki J; Wada H; Marubashi S; Nagano H; Doki Y; Mori M; Ishii H
    Cancer Sci; 2015 Sep; 106(9):1182-7. PubMed ID: 26298849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of miRNAs in cancer: from pathogenesis to therapeutic implications.
    Seven M; Karatas OF; Duz MB; Ozen M
    Future Oncol; 2014 May; 10(6):1027-48. PubMed ID: 24941988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs and cancer stem cells: the sword and the shield.
    Sun X; Jiao X; Pestell TG; Fan C; Qin S; Mirabelli E; Ren H; Pestell RG
    Oncogene; 2014 Oct; 33(42):4967-77. PubMed ID: 24240682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of iPS cell technology to cancer epigenome study: uncovering the mechanism of cell status conversion for drug resistance in tumor.
    Matsuda Y; Semi K; Yamada Y
    Pathol Int; 2014 Jul; 64(7):299-308. PubMed ID: 25047500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA regulation of cancer metabolism: role in tumour suppression.
    Tomasetti M; Santarelli L; Neuzil J; Dong L
    Mitochondrion; 2014 Nov; 19 Pt A():29-38. PubMed ID: 24960472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of CaSR expression circumvents the molecular features of malignant CaSR null colon cancer cells.
    Singh N; Chakrabarty S
    Int J Cancer; 2013 Nov; 133(10):2307-14. PubMed ID: 23674327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and epigenetic down-regulation of microRNA-212 promotes colorectal tumor metastasis via dysregulation of MnSOD.
    Meng X; Wu J; Pan C; Wang H; Ying X; Zhou Y; Yu H; Zuo Y; Pan Z; Liu RY; Huang W
    Gastroenterology; 2013 Aug; 145(2):426-36.e1-6. PubMed ID: 23583431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.